Drug Trial Radar · NCT01462344
6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
Last checked: Nov 19, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,250
Actual
Start
Nov 17, 2011
Primary completion
Nov 1, 2015
Study completion Nov 3, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Oct 31, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.
Conditions
- Asthma
Interventions
ADVAIR 100/50mcgDrug
fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
ADVAIR 250/50mcgDrug
fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
FLOVENT 100mcgDrug
fluticasone propionate (100) twice daily (AM and PM) for 6 months
FLOVENT 250mcgDrug
fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)Time frame: From Day 1 up to 6 months
- Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment PeriodTime frame: From Day 1 up to 6 months
Locations
530 sites in 32 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Montgomery, Alabama
GSK Investigational Site
Scottsboro, Alabama
GSK Investigational Site
Toney, Alabama
GSK Investigational Site
Tuscaloosa, Alabama
GSK Investigational Site
Dothan, Alaska
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Bentonville, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Alhambra, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Canoga Park, California
GSK Investigational Site
Dinuba, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Gold River, California
GSK Investigational Site
Granada Hills, California
GSK Investigational Site
Harbor City, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Huntington Park, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Napa, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Orange, California
GSK Investigational Site
Palmdale, California
GSK Investigational Site
Paramount, California
Showing 40 of 530 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.